Keymed Biosciences Announces Approval Of Stapokibart For The Treatment Of Chronic Rhinosinusitis With Nasal Polyposis

About Stapokibart About Stapokibart Stapokibart (trade name: Kangyueda, R&D codename: CM310) is a high-efficient, humanized antibody targeting the interleukin-4 receptor alpha subunit (IL-4Rα), and is the first domestically manufactured IL-4Rα antibody drug granted marketing approval by the NMPA. By targeting IL-4Rα, Stapokibart can block both interleukin-4 (IL-4) and interleukin-13 (IL-13) signaling. IL-4 and IL-13 are two key cytokines that trigger type II inflammation. Stapokibart...

CHENGDU, China, 23/12/2024 (informazione.news - comunicati stampa - salute e benessere)

Stapokibart (trade name: Kangyueda, R&D codename: CM310) is a high-efficient, humanized antibody targeting the interleukin-4 receptor alpha subunit (IL-4Rα), and is the first domestically manufactured IL-4Rα antibody drug granted marketing approval by the NMPA. By targeting IL-4Rα, Stapokibart can block both interleukin-4 (IL-4) and interleukin-13 (IL-13) signaling. IL-4 and IL-13 are two key cytokines that trigger type II inflammation. Stapokibart has demonstrated good safety and encouraging efficacy in multiple previous clinical trials, and its treatment of the indication of moderate-to-severe atopic dermatitis in adults has been approved for marketing in September 2024 . As of the date of this announcement, the new drug application of Stapokibart for the treatment of seasonal allergic rhinitis has been accepted by the NMPA.

View original content:https://www.prnewswire.co.uk/news-releases/keymed-biosciences-announces-approval-of-stapokibart-for-the-treatment-of-chronic-rhinosinusitis-with-nasal-polyposis-302338405.html